Assessment of systemic inflammation activity, myocardial structure and functional features, their relationship in patients with multiple myeloma, receiving bortezomib therapy

Aim. To study the dynamics of calculated indices [neutrophil-lymphocyte ratio (NLR); systemic inflammation index (SIV)] and biomarkers of systemic inflammation [interleukin-1β (IL-1β); high-sensitivity C-reactive protein (hsCRP)], parameters of the structure-and-function state of the myocardium and intracardiac hemodynamics, and their relationship in patients newly diagnosed with multiple myeloma (MM) at the onset of the disease and after 6 courses of chemotherapy (CT) containing the proteasome inhibitor bortezomib.

Material and methods. This prospective study included 30 patients aged 63.8±10.0 years diagnosed with MM; 17 (56.7 %) of them were men. The following tests were performed for all patients: measurement of IL-1β and hsCRP, calculation of the inflammation indexes NLR and SIV, transthoracic echocardiography before and after 6 courses of bortezomib-containing CT. At the time of study completion, 9 patients dropped out due to reasons not related to cardiovascular complications of CT.

Results. The antitumor therapy was associated with increases of immune-inflammation indexes: NLR increased from 1.54 [1.02; 1.83] to 2.9 [1.9; 4.35] (p=0.009) and SIV increased from 402.95 [230.5; 534.0] to 1102.2 [453.1; 1307.9] (р=0.014). IL-1β increased from 5.15 [4.05; 5.77] to 6.22 [5.66; 6.52] pg/ml remaining within the reference range (p=0.142) whereas hsCRP decreased from 1.02 [0.02; 2.71] to 0.02 [0.02; 0.82] IU/l (p=0.138). Statistically significant changes in parameters of heart remodeling and clinical picture of cardiovascular complications were not observed. A correlation analysis showed significant inverse correlations of hsCRP with left ventricular ejection fraction (LV EF) (r= –0.557; p=0.003), the number of plasma cells (PC) with LV EF (r= –0.443; p=0.023), and a direct correlation of the number of PC with hsCRP (r=0.433; p=0.022).

Conclusion. During the study, the accepted criteria for cardiotoxicity of bortezomib-containing chemotherapy in patients with MM, were not met. The identified correlations between the level of markers for acute inflammation, indexes of intracardiac hemodynamics, and the immediate MM substrate may indicate the role of chronic low-intensity inflammation in the pathogenesis of myocardial remodeling in patients with MM. This necessitates further studies on larger samples of patients to assess the prognostic significance.

1. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European Heart Journal. 2020;41(18):1720–9. DOI: 10.1093/eurheartj/ehaa006

2. Wang L, Wang F, Chen L, Geng Y, Yu S, Chen Z. Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an American population-based cohort study. European Heart Journal. 2021;42(1):101–9. DOI: 10.1093/eurheartj/ehaa779

3. Campia U. Vascular effects of cancer treatments. Vascular Medicine. 2020;25(3):226–34. DOI: 10.1177/1358863X20914978

4. Gumerova K.S., Sakhautdinova G.M., Polyakova I.M. Antitumour Drug Induced Cardiovascular Toxicity and Current Tumour Treatment Methods. Creative surgery and oncology. 2020;9(4):285–92. DOI: 10.24060/2076-3093-2019-9-4-285-292

5. Wang L, Cheng CK, Yi M, Lui KO, Huang Y. Targeting endothelial dysfunction and inflammation. Journal of Molecular and Cellular Cardiology. 2022;168:58–67. DOI: 10.1016/j.yjmcc.2022.04.011

6. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2020 (morbidity and mortality). -M.: P.A. Herzen MSRI branch of the FSBI ‘NMIC of Radiology’ MH RF;2021. - 252 p. ISBN 978-5-85502-268-1

7. Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A et al. Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018;103(9):1422–32. DOI: 10.3324/haematol.2018.191288

8. Wu P, Oren O, Gertz MA, Yang EH. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management. Current Oncology Reports. 2020;22(7):66. DOI: 10.1007/s11912-020-00931-w

9. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244

10. Barac YD, Emrich F, Krutzwakd-Josefson E, Schrepfer S, Sampaio LC, Willerson JT et al. The ubiquitin-proteasome system: A potential therapeutic target for heart failure. The Journal of Heart and Lung Transplantation. 2017;36(7):708–14. DOI: 10.1016/j.healun.2017.02.012

11. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple Facets of NFκB in the Heart: To Be or Not to NF-κB. Circulation Research. 2011;108(9):1122–32. DOI: 10.1161/CIRCRESAHA.110.226928

12. Wei Q, Xia Y. Proteasome Inhibition Down-regulates Endothelial Nitricoxide Synthase Phosphorylation and Function. Journal of Biological Chemistry. 2006;281(31):21652–9. DOI: 10.1074/jbc.M602105200

13. Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S. Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. Mediators of Inflammation. 2017;2017:1852517. DOI: 10.1155/2017/1852517

14. Yang J, Liu Z, Liu H, He J, Yang J, Lin P et al. C-reactive protein promotes bone destruction in human myeloma through the CD32–p38 MAPK–Twist axis. Science Signaling. 2017;10(509):eaan6282. DOI: 10.1126/scisignal.aan6282

15. Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X et al. Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules. 2018;8(3):80. DOI: 10.3390/biom8030080

16. Ruparelia N, Choudhury R. Inflammation and atherosclerosis: what is on the horizon? Heart. 2020;106(1):80–5. DOI: 10.1136/heartjnl-2018-314230

17. Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, GonzálezGarrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. International Journal of Molecular Sciences. 2021;22(8):3850. DOI: 10.3390/ijms22083850

18. Mendeleeva L.P., Votiakova O.M., Rekhtina I.G., Osmanov E.A., Poddubnaya I.V., Grivtsova L.Yu. et al. Multiple myeloma. Journal of Modern Oncology. 2021;22(4):6–28. DOI: 10.26442/18151434.2020.4.200457

19. Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Bladé J et al. International Staging System for Multiple Myeloma. Journal of Clinical Oncology. 2005;23(15):3412–20. DOI: 10.1200/JCO.2005.04.242

20. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54. DOI: 10.1002/1097-0142(197509)36:33.0.co;2-u

21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology. 1982;5(6):649–55. PMID: 7165009

22. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2021;42(16):1554–68. DOI: 10.1093/eurheartj/ehab072

23. Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Shupenina E.Yu., Ballyuzek M.F., Barinova I.V. et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):152–233. DOI: 10.15829/1560-4071-2021-4703

24. Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Bayo Jimenez MT et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxidative Medicine and Cellular Longevity. 2019;2019:7092151. DOI: 10.1155/2019/7092151

25. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383(19):1838–47. DOI: 10.1056/NEJMoa2021372

26. Danforth DN. The Role of Chronic Inflammation in the Development of Breast Cancer. Cancers. 2021;13(15):3918. DOI: 10.3390/cancers13153918

27. Watanabe S, Hibiya S, Katsukura N, Kitagawa S, Sato A, Okamoto R et al. Influence of chronic inflammation on the malignant phenotypes and the plasticity of colorectal cancer cells. Biochemistry and Biophysics Reports. 2021;26:101031. DOI: 10.1016/j.bbrep.2021.101031

28. Ballerini P, Contursi A, Bruno A, Mucci M, Tacconelli S, Patrignani P. Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies. Frontiers in Pharmacology. 2022;13:838079. DOI: 10.3389/fphar.2022.838079

29. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute. 2014;106(6):dju124. DOI: 10.1093/jnci/dju124

30. Wen J, Bedford M, Begum R, Mitchell H, Hodson J, Whiting J et al. The value of inflammation based prognostic scores in patients undergoing surgical resection for oesophageal and gastric carcinoma. Journal of Surgical Oncology. 2018;117(8):1697–707. DOI: 10.1002/jso.25057

31. Yu W, Dou Y, Wang K, Liu Y, Sun J, Gao H et al. Preoperative neutrophil lymphocyte ratio but not platelet lymphocyte ratio predicts survival and early relapse in patients with oral, pharyngeal, and lip cancer. Head & Neck. 2019;41(5):1468–74. DOI: 10.1002/hed.25580

32. Yang L, Huang Y, Zhou L, Dai Y, Hu G. High pretreatment neutrophil‐ to‐lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta‐analysis. Head & Neck. 2019;41(5):1525–35. DOI: 10.1002/hed.25583

33. Minardi D, Scartozzi M, Montesi L, Santoni M, Burattini L, Bianconi M et al. Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. SpringerPlus. 2015;4(1):255. DOI: 10.1186/s40064-015-1036-1

34. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119–31. DOI: 10.1056/NEJMoa1707914

35. Baylis RA, Gomez D, Mallat Z, Pasterkamp G, Owens GK. The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology. Arteriosclerosis, Thrombosis, and Vascular Biology. 2017;37(11):e174–7. DOI: 10.1161/ATVBAHA.117.310097

36. Costes V, Portier M, Lu Z-Y, Rossi J-F, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production: IL-1 Gene Expression in Multiple Myeloma. British Journal of Haematology. 1998;103(4):1152–60. DOI: 10.1046/j.1365-2141.1998.01101.x

37. Hofbauer D, Mougiakakos D, Broggini L, Zaiss M, Büttner-Herold M, Bach C et al. β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. Immunity. 2021;54(8):1772-1787.e9. DOI: 10.1016/j.immuni.2021.07.002

38. Lust JA, Lacy MQ, Zeldenrust SR, Witzig TE, Moon-Tasson LL, Dinarello CA et al. Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. American Journal of Hematology. 2016;91(6):571–4. DOI: 10.1002/ajh.24352

39. Shnalieva N.A., Salogub G.N. Cardiotoxicity of proteasome inhibitors in multiple myeloma treatment: literature review and own data. Medline.ru. Russian Biomedical Journal. 2022;23(1):246–61. http://www.medline.ru/public/art/tom23/art16.html]

40. Dinarello CA. Targeting the Pathogenic Role of Interleukin 1β in the Progression of Smoldering/Indolent Myeloma to Active Disease. Mayo Clinic Proceedings. 2009;84(2):105–7. DOI: 10.4065/84.2.105

41. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013;62(4):263–71. DOI: 10.1016/j.jacc.2013.02.092

42. Xiao Y, Yin J, Wei J, Shang Z. Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis. PLoS ONE. 2014;9(1):e87671. DOI: 10.1371/journal.pone.0087671

43. Gurram MK, Pulivarthi S, Ehresmann K, Mathew J. Cardiotoxicity associated with bortezomib: A single-center experience. Journal of Cancer Research and Therapeutics. 2017;13(6):961–3. DOI: 10.4103/0973-1482.172126

44. Orciuolo E, Buda G, Cecconi N, Galimberti S, Versari D, Cervetti G et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. British Journal of Haematology. 2007;138(3):396–7. DOI: 10.1111/j.1365-2141.2007.06659.x

45. Honton B, Despas F, Dumonteil N, Rouvellat C, Roussel M, Carrie D et al. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database. Fundamental & Clinical Pharmacology. 2014;28(3):349–52. DOI: 10.1111/fcp.12039

46. Diwadkar S, Patel AA, Fradley MG. Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity. Case Reports in Cardiology. 2016;2016:3456287. DOI: 10.1155/2016/3456287

47. Fujiwara M, Uchida M, Endo M, Goto M, Shimizu T. Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors. Oncology. 2023;101(5):343–8. DOI: 10.1159/000529341

48. Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, Nakao S. Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. International Journal of Hematology. 2010;91(5):903–6. DOI: 10.1007/s12185-010-0586-9

49. Burkhart T, Keith MCL, Lenneman CAG, Fernando RR. BortezomibInduced Cardiac Tamponade in a 49-Year-Old Man. Texas Heart Institute Journal. 2018;45(4):260–3. DOI: 10.14503/THIJ-17-6242

50. Iqubal A, Iqubal MK, Sharma S, Ansari MohdA, Najmi AK, Ali SM et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sciences. 2019;218:112–31. DOI: 10.1016/j.lfs.2018.12.018

51. De Salvi Guimarães F, De Moraes WMAM, Bozi LHM, Souza PR, Antonio EL, Bocalini DS et al. Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation. Molecular and Cellular Biochemistry. 2017;424(1–2):87–98. DOI: 10.1007/s11010-016-2846-3